Parkinson F E, Clanachan A S
Department of Pharmacology, University of Alberta, Edmonton, Canada.
Eur J Pharmacol. 1989 Apr 12;163(1):69-75. doi: 10.1016/0014-2999(89)90396-8.
We evaluated the interaction of several nucleoside transport inhibitors and substrates with the binding of [3H]nitrobenzylthioinosine ([3H]NBMPR) to nucleoside transport sites in guinea pig cardiac sections. Using quantitative autoradiography, we determined inhibition constants for inhibition of [3H]NBMPR binding to both coronary endothelial cells and cardiac myocytes. We studied the interactions of NBMPR, nitrobenzylthioguanosine, dipyridamole, dilazep, hexobendine, lidoflazine, mioflazine, soluflazine, adenosine, inosine and uridine for these two cell types. Of the compounds tested in this study, lidoflazine (8.2X) and hexobendine (6.3X) have the greatest selectivity for coronary endothelial cell nucleoside transporters. All other compounds had 3-fold or less selectivity. Therefore, there is evidence of nucleoside transporter subtypes between endothelial cells and myocytes. This heterogeneity of transport inhibitory sites on nucleoside transporters may allow the development of agents to modulate selectively some of the cardiovascular effects of adenosine.
我们评估了几种核苷转运抑制剂和底物与[3H]硝基苄硫基肌苷([3H]NBMPR)在豚鼠心脏切片中与核苷转运位点结合的相互作用。使用定量放射自显影技术,我们确定了[3H]NBMPR与冠状动脉内皮细胞和心肌细胞结合的抑制常数。我们研究了NBMPR、硝基苄硫基鸟苷、双嘧达莫、地拉齐普、己酮可可碱、利多氟嗪、米氟嗪、索氟嗪、腺苷、肌苷和尿苷对这两种细胞类型的相互作用。在本研究中测试的化合物中,利多氟嗪(8.2倍)和己酮可可碱(6.3倍)对冠状动脉内皮细胞核苷转运体具有最大的选择性。所有其他化合物的选择性为3倍或更低。因此,有证据表明内皮细胞和心肌细胞之间存在核苷转运体亚型。核苷转运体上这种转运抑制位点的异质性可能有助于开发选择性调节腺苷某些心血管效应的药物。